Print

Visterra, Inc. Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against the H5N1 (Avian Flu) Influenza Strain in Hanoi, Viet Nam  
10/29/2012 6:57:38 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., developer of novel medicines to prevent and treat infectious and other major diseases, today announced that its Chief Medical Officer, Donna Ambrosino, MD, has been invited by the International Society for Influenza and Other Respiratory Virus Diseases (isirv) to present VIS410 at its Antiviral Group (isirv-AVG) Conference entitled “Severe Influenza: Burden, Pathogenesis and Management” being held in Hanoi, Viet Nam on October 29-31, 2012. The isirv-AVG is an independent and international scientific professional society which has lead responsibility for organizing the largest international conference exclusively devoted to influenza prevention, control and treatment, including seasonal flu and pandemic preparedness.